Practical Strategies for Improving Outcomes in MDS: New HMAs, Combination and Novel Treatments

Practical Strategies for Improving Outcomes in MDS: New HMAs, Combination and Novel Treatments
Practical Strategies for Improving Outcomes in MDS: New HMAs, Combination and Novel Treatments
CME, CPE
Aziz Nazha, MD
Release Date: February 26, 2020
Expiration Date: February 26, 2021

Risk stratification is critical when managing patients with MDS because guideline consensus treatment algorithms are distinguished by lower-risk disease and higher-risk disease. In this activity, Dr. Aziz Nazha explains next steps after risk stratifying your patient and the goal of therapy based on this assessment. He will also review novel formulations of hypomethylating agents (HMAs) in development and their potential use in MDS. Lastly, Dr. Nazha will cover key genetic mutations and the potential future investigations.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology
Begin, Earn CreditView Only, No CreditGet Certificate
 

MediCom Worldwide, Inc. would like to thank Celgene Corporation and Onconova Therapeutics Inc. for their educational support of ManagingMDS.com

©2020 MediCom Worldwide, Inc. All rights reserved